US 12,414,970 B2
Bacillus coagulans and Bacillus subtilis for the prevention and treatment of functional gastro-intestinal disorders
Raf Dybajlo, Lummen (BE); Wannes Thys, Bilzen (BE); Lucas Wauters, Leuven (BE); and Tim Vanuytsel, Leuven (BE)
Assigned to My Health International, Diepenbeek (BE)
Appl. No. 17/599,104
Filed by MY RESEARCH, Lummen (BE)
PCT Filed Mar. 27, 2020, PCT No. PCT/EP2020/058850
§ 371(c)(1), (2) Date Sep. 28, 2021,
PCT Pub. No. WO2020/201153, PCT Pub. Date Oct. 8, 2020.
Claims priority of application No. 2019/5201 (BE), filed on Mar. 29, 2019.
Prior Publication US 2022/0160793 A1, May 26, 2022
Int. Cl. A61P 1/00 (2006.01); A23L 2/52 (2006.01); A23L 33/00 (2016.01); A23L 33/135 (2016.01); A61K 35/742 (2015.01); A61K 45/06 (2006.01); A61P 1/14 (2006.01); A61K 35/00 (2006.01)
CPC A61K 35/742 (2013.01) [A23L 2/52 (2013.01); A23L 33/135 (2016.08); A23L 33/40 (2016.08); A61K 45/06 (2013.01); A61P 1/14 (2018.01); A23V 2002/00 (2013.01); A61K 2035/115 (2013.01)] 13 Claims
OG exemplary drawing
 
1. A method for treating a functional gastroduodenal disorder in a subject in need thereof, the method comprising administering to the subject a combination comprising Bacillus subtilis spores and Bacillus coagulans spores,
wherein the B. subtilis spores are derived from strain MY02 as deposited with Belgian Co-ordinated Collection of Micro-Organisms (BCCM) with accession number LMG P-31319, and
wherein the B. coagulans spores are derived from strain MY01 as deposited with the BCCM with accession number LMG P-31318.